SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.
Study Type
OBSERVATIONAL
Enrollment
3,000
If the patient agrees, the center will send a link to the questionnaires via email. Patients who have completed the questionnaires will be analyzed in the SEMAFOLLOW study. Estimated time to complete the questionnaire: approximately 30 minutes
Nantes university hospital
Nantes, France
Describe weight changes during the follow-up period according to patient characteristics.
Time frame: Baseline
Identify the characteristics of patients who continue treatment or switch to other obesity management strategies and the associated factors.
Time frame: Baseline
Compare the profiles of responders and non-responders
Time frame: Baseline
Describe weight change according to different subpopulations.
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.